(NASDAQ: TNDM) Tandem Diabetes Care's forecast annual revenue growth rate of 9.96% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Tandem Diabetes Care's revenue in 2026 is $1,041,417,000.On average, 26 Wall Street analysts forecast TNDM's revenue for 2026 to be $76,119,105,458, with the lowest TNDM revenue forecast at $72,501,012,694, and the highest TNDM revenue forecast at $79,041,411,152. On average, 26 Wall Street analysts forecast TNDM's revenue for 2027 to be $85,373,073,489, with the lowest TNDM revenue forecast at $79,458,883,394, and the highest TNDM revenue forecast at $93,305,046,087.
In 2028, TNDM is forecast to generate $96,783,981,437 in revenue, with the lowest revenue forecast at $87,808,328,234 and the highest revenue forecast at $111,117,195,079.